Pfizer has agreed to pay $93 million to settle antitrust claims that it conspired with India's Ranbaxy Laboratories to delay sales of generic versions of the cholesterol drug Lipitor. The settlement, which requires court approval, comes after a decade of litigation and provides relief to purchasers of Lipitor while avoiding the risk of continued litigation.